MDD
MCID: DPR016
MIFTS: 73

Depression (MDD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Depression

MalaCards integrated aliases for Depression:

Name: Depression 26 30 44 64
Depressive Disorder 26 56 74
Major Depressive Disorder 26 74
Unipolar Depression 26 74
Clinical Depression 26 74
Depressive Syndrome 56 74
Major Depression 26 56
Mental Depression 74
Mdd 26

Classifications:



Summaries for Depression

MedlinePlus : 44 Depression is a serious medical illness. It's more than just a feeling of being sad or "blue" for a few days. If you are one of the more than 19 million teens and adults in the United States who have depression, the feelings do not go away. They persist and interfere with your everyday life. Symptoms can include Feeling sad or "empty" Loss of interest in favorite activities Overeating, or not wanting to eat at all Not being able to sleep, or sleeping too much Feeling very tired Feeling hopeless, irritable, anxious, or guilty Aches or pains, headaches, cramps, or digestive problems Thoughts of death or suicide Depression is a disorder of the brain. There are a variety of causes, including genetic, biological, environmental, and psychological factors. Depression can happen at any age, but it often begins in teens and young adults. It is much more common in women. Women can also get postpartum depression after the birth of a baby. Some people get seasonal affective disorder in the winter. Depression is one part of bipolar disorder. There are effective treatments for depression, including antidepressants, talk therapy, or both. NIH: National Institute of Mental Health

MalaCards based summary : Depression, also known as depressive disorder, is related to postpartum depression and atypical depressive disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Depression is BDNF-AS (BDNF Antisense RNA), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and breast, and related phenotypes are behavior/neurological and homeostasis/metabolism

Genetics Home Reference : 26 Depression (also known as major depression or major depressive disorder) is a psychiatric disorder that affects mood, behavior, and overall health. It causes prolonged feelings of sadness, emptiness, or hopelessness, and a loss of interest in activities that were once enjoyed. People with depression may also have changes in appetite (leading to overeating or not eating enough), changes in sleeping patterns (sleeping too much or not being able to sleep), loss of energy, and difficulty concentrating. Although depression is considered primarily a mental health disorder, it can also have physical features including headaches, other unexplained aches and pains, unusually slow or fast movements, and digestive problems. To be diagnosed with depression, an individual must have signs and symptoms nearly every day for at least 2 weeks. However, the features of this condition vary widely.

PubMed Health : 64 About depression: We all feel sad or lethargic every now and then. And we have all felt down or even desperate at some point in our lives. These phases are a normal part of life, and people usually feel better again after a while. Things are different for people who have depression. Their sadness and negative thoughts last longer and overshadow all of their thoughts and actions. Depression can arise without any triggering events or for no apparent reasons. People often feel like they are stuck in a black hole. They feel cheerless, lack motivation and self-confidence, and think of themselves as worthless. This can make it difficult to do everyday things like going to work or studying. Friends, family and hobbies are often neglected. They don't sleep well.Depression can also make family and friends feel worried, anxious and helpless. Often they want to help but don't know how. It's not always easy for them to tell whether it's a passing phase or a serious illness.

Related Diseases for Depression

Diseases related to Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1451)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 34.3 BDNF CRH MAOA SLC6A4
2 atypical depressive disorder 34.1 CRH HTR2A MAOA SLC6A4
3 endogenous depression 33.9 BDNF CRH CRHR1 HTR1A HTR2A MAOA
4 major depressive disorder 33.5 BDNF CRH CRHR1 DISC2 HTR1A HTR2A
5 mental depression 33.4 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
6 dysthymic disorder 32.6 HTR2A MAOA SLC6A4
7 eating disorder 32.4 BDNF CRH HTR2C SLC6A4
8 fibromyalgia 32.4 CRH HTR2A SLC6A4
9 bipolar disorder 32.3 BDNF DISC2 HTR1A HTR2A PDLIM5 RELN
10 bulimia nervosa 32.2 BDNF HTR2A SLC6A4
11 irritable bowel syndrome 32.2 CRH CRHR1 SLC6A4
12 schizoaffective disorder 32.2 BDNF DISC2 HTR2A SLC6A4
13 anxiety 32.1 BDNF CRH CRHR1 HTR1A HTR2A HTR2C
14 bipolar i disorder 32.0 BDNF HTR1A HTR2A HTR2C SLC6A4
15 migraine with or without aura 1 31.9 HTR1A HTR2A HTR2C MAOA SLC6A4
16 parkinson disease, late-onset 31.8 BDNF HTR1A HTR2A MAOA NOS1 SLC6A4
17 borderline personality disorder 31.8 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
18 autism spectrum disorder 31.3 BDNF DISC2 HTR2A RELN SLC6A4 TPH2
19 mood disorder 31.2 BDNF CRH CRHR1 DISC2 HTR1A HTR2A
20 personality disorder 31.1 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
21 post-traumatic stress disorder 31.0 BDNF CRH HTR2A MAOA SLC6A4
22 alcohol abuse 31.0 BDNF HTR2A SLC6A4
23 sexual disorder 31.0 HTR1A NOS1 SLC6A4
24 substance abuse 31.0 BDNF MAOA SLC6A4
25 panic disorder 30.9 CRH HTR1A HTR2A MAOA SLC6A4 TPH2
26 generalized anxiety disorder 30.9 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
27 social phobia 30.8 HTR1A MAOA SLC6A4
28 anorexia nervosa 30.8 BDNF CRH HTR2A SLC6A4
29 tobacco addiction 30.7 HTR2A MAOA SLC6A4
30 agoraphobia 30.7 HTR1A MAOA SLC6A4
31 chronic fatigue syndrome 30.7 CRH HTR1A HTR2A MAOA SLC6A4 TPH2
32 substance dependence 30.6 BDNF MAOA SLC6A4
33 alcohol dependence 30.6 BDNF CRHR1 HTR1A HTR2A HTR2C MAOA
34 autism 30.5 BDNF HTR1A HTR2A RELN SLC6A4
35 drug dependence 30.4 BDNF CRH SLC6A4
36 obsessive-compulsive disorder 30.4 BDNF CRH HTR1A HTR2A HTR2C MAOA
37 oppositional defiant disorder 30.4 MAOA SLC6A4 TPH2
38 attention deficit-hyperactivity disorder 30.4 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
39 temporal lobe epilepsy 30.3 BDNF HTR1A RELN
40 pathological gambling 30.2 HTR2A MAOA SLC6A4
41 premature ejaculation 30.2 HTR1A HTR2C SLC6A4
42 paranoid schizophrenia 30.2 BDNF HTR2A MAOA SLC6A4 TPH2
43 fragile x syndrome 30.2 BDNF GRIA1 GRM1 SLC6A4
44 serotonin syndrome 30.1 HTR1A HTR2A MAOA SLC6A4
45 status epilepticus 30.0 BDNF GRIA1 GRIA2
46 kleptomania 30.0 HTR1A MAOA SLC6A4
47 migraine without aura 30.0 GRIA1 HTR1A SLC6A4
48 amyotrophic lateral sclerosis 1 30.0 BDNF GRIA1 GRIA2 GRM1 NOS1
49 hypoactive sexual desire disorder 29.7 HTR1A HTR2A
50 early-onset schizophrenia 29.7 BDNF HTR2A

Graphical network of the top 20 diseases related to Depression:



Diseases related to Depression

Symptoms & Phenotypes for Depression

UMLS symptoms related to Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

MGI Mouse Phenotypes related to Depression:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
2 homeostasis/metabolism MP:0005376 10.25 BDNF CRH CRHR1 GRIA1 GRIA2 GRID2
3 growth/size/body region MP:0005378 10.23 BDNF CRH GRIA1 GRIA2 GRIA3 GRID2
4 nervous system MP:0003631 10.19 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
5 mortality/aging MP:0010768 10.18 BDNF CRHR1 GRIA2 GRIA3 GRID2 GRM1
6 integument MP:0010771 10.1 BDNF CRH GRIA1 GRIA2 GRIA3 GRM1
7 muscle MP:0005369 9.92 GRID2 GRM1 HTR2A HTR2C NOS1 PDLIM5
8 no phenotypic analysis MP:0003012 9.85 BDNF CRH CRHR1 GRIA1 GRIA2 GRIA3
9 normal MP:0002873 9.56 BDNF CRH CRHR1 GRIA1 GRIA2 NOS1
10 reproductive system MP:0005389 9.28 BDNF GRIA2 GRIA3 GRID2 GRM1 NOS1

Drugs & Therapeutics for Depression

PubMedHealth treatment related to Depression: 64

Many people who have depression find it hard to accept that fact. One possible reason for this is that they are ashamed about having a mental health problem and don't want their friends, family and colleagues to find out. Some people don't want to have treatment as a result. But treatment can often shorten depressive episodes and relieve people's symptoms.There are various treatment options for depression. The main treatments are psychological treatment, such as cognitive behavioral therapy, and/or medication. Which type of treatment is the most appropriate, where it should take place and how long it lasts will depend on several factors, including how severe the person’s depression is, their personal circumstances, and how their symptoms develop over time. People can talk to a therapist about the advantages and disadvantages of the possible treatments, as well as what they expect from treatment and any fears they might have.

Drugs for Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
4
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 34841-39-9, 34911-55-2 444
5
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
6
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
7
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68-41-7 401 6234
8
Parathyroid hormone Approved, Investigational Phase 4,Phase 1,Not Applicable 9002-64-6
9
Clonazepam Approved, Illicit Phase 4,Phase 2,Early Phase 1,Not Applicable 1622-61-3 2802
10
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 91374-21-9, 91374-20-8 5095 497540
11
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
12
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
13
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54739-18-3 3404 5324346
14
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
15
Angiotensin II Approved, Investigational Phase 4,Phase 3 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
18
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
19
Reboxetine Approved, Experimental Phase 4,Phase 2,Not Applicable 98769-81-4, 71620-89-8 65856 123628
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
21
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61337-67-5, 85650-52-8 4205
22
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-03-3
23
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
24
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 19794-93-5 5533
25
Copper Approved, Investigational Phase 4,Phase 3 7440-50-8 27099
26
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 1,Not Applicable 57-63-6 5991
27
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
28
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 28014-46-2
29
Norethindrone Approved Phase 4 68-22-4 6230
30
Eszopiclone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 138729-47-2 969472
31
Buspirone Approved, Investigational Phase 4,Phase 2,Not Applicable 36505-84-7 2477
32
Nortriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 72-69-5 4543
33
Trimipramine Approved Phase 4 739-71-9 5584 4055
34
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
35
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
36
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
37
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 508233-74-7 9966051
38
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 28523-86-6 5206
39
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
40
Lactulose Approved Phase 4 4618-18-2 11333
41
Methimazole Approved Phase 4 60-56-0 1349907
42
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-18-4 6010
43
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5949-44-0
44
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-22-0, 481-30-1 6013 10204
45
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Not Applicable 315-37-7 9416
46
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
47
Succinylcholine Approved Phase 4,Not Applicable 306-40-1 5314
48
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 616-91-1 12035
49
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
50
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Not Applicable 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 10133)
# Name Status NCT ID Phase Drugs
1 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
2 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
3 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
4 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
5 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
6 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
7 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
8 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
9 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
10 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
11 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
12 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
13 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
14 Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
15 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
16 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
17 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
18 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
19 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
20 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
21 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
22 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
23 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
24 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
25 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
26 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
27 Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
28 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
29 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
30 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
31 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
32 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
33 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
34 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
35 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
36 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
37 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
38 Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
39 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
40 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
41 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
42 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
43 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
44 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
45 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
46 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
47 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
48 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
49 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
50 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo

Search NIH Clinical Center for Depression

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Depression

Genetic tests related to Depression:

# Genetic test Affiliating Genes
1 Depression 30

Anatomical Context for Depression

MalaCards organs/tissues related to Depression:

42
Brain, Heart, Breast, Testes, Lung, Prostate, Cortex

Publications for Depression

Articles related to Depression:

(show top 50) (show all 19722)
# Title Authors Year
1
Socioeconomic status and depression as combined risk factors for acute myocardial infarction and stroke: A population-based study of 2.7 million Korean adults. ( 30712815 )
2019
2
Correction to: Waiting for Godot: Engaging in Discussions About Depression Care in Patients With Acute Myocardial Infarction While Waiting for a Definitive Trial That Never Appears. ( 30640543 )
2019
3
Efficacy and feasibility of a humor training for people suffering from depression, anxiety, and adjustment disorder: a randomized controlled trial. ( 30894148 )
2019
4
Depression and aging with HIV: Associations with health-related quality of life and positive psychological factors. ( 30884371 )
2019
5
Induction of Metabotropic Glutamate Receptor-Mediated Long-Term Depression in the Hippocampal Schaffer Collateral Pathway of Aging Rats. ( 30707430 )
2019
6
Assessing the relationship between multimorbidity and depression in older men and women: the International Mobility in Aging Study (IMIAS). ( 30724575 )
2019
7
Pharmacotherapeutic options for co-morbid depression and alcohol dependence. ( 30602322 )
2019
8
Fearful Attachment Linked to Childhood Abuse, Alexithymia, and Depression in Motor Functional Neurological Disorders. ( 30376786 )
2019
9
Internet gaming disorder in male and female young adults: The role of alexithymia, depression, anxiety and gaming type. ( 30616119 )
2019
10
Alexithymia, Suicide Ideation and Homocysteine Levels in Drug Naïve Patients with Major Depression: A Study in the “Real World” Clinical Practice. ( 30905133 )
2019
11
Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. ( 30649133 )
2019
12
The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment. ( 30910421 )
2019
13
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2019
14
Frontal lobe dysfunction as a predictor of depression and anxiety following temporal lobe epilepsy surgery. ( 30909053 )
2019
15
Maternity blues: a risk factor for anhedonia, anxiety, and depression components of Edinburgh Postnatal Depression Scale. ( 30909766 )
2019
16
Efficacy of a transdiagnostic, video-based online program for reducing depression, anxiety, and suicidal ideation in adults: Protocol for a randomised controlled trial. ( 30911696 )
2019
17
Effect of Sexual Rehabilitation Program on Anxiety, Stress, Depression and Sexual Function among Men with Coronary Artery Disease. ( 30912471 )
2019
18
Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. ( 30873251 )
2019
19
Diagnostic validity of the anxiety and depression questions from the Well-Being Process Questionnaire. ( 30873498 )
2019
20
Differentiating acute suicidal affective disturbance (ASAD) from anxiety and depression Symptoms: A network analysis. ( 30875677 )
2019
21
Alpha-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. ( 30877025 )
2019
22
A randomised controlled trial of 'MUMentum postnatal': Internet-delivered cognitive behavioural therapy for anxiety and depression in postpartum women. ( 30877878 )
2019
23
The impact of pre-operative telephone support and education on symptoms of anxiety, depression, pain and quality of life post total knee replacement: An exploratory case study. ( 30879955 )
2019
24
Utility of Anxiety or Depression domain of EQ-5D to Define Psychological Distress in Spine Surgery. ( 30880196 )
2019
25
Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report. ( 30880405 )
2019
26
Depression with high levels of anxiety. ( 30882425 )
2019
27
A meta-analysis of randomized controlled trials of laughter and humor interventions on depression, anxiety and sleep quality in adults. ( 30882915 )
2019
28
Transcranial photobiomodulation prevents anxiety and depression via changing serotonin and nitric oxide levels in brain of depression model mice: A study of three different doses of 810 nm laser. ( 30883832 )
2019
29
The impacts of depression and anxiety on quality of life among patients with HIV/AIDS and their spouses: testing dyadic dynamics using the actor-partner interdependence model. ( 30884955 )
2019
30
Contextual and historical factors for increased levels of anxiety and depression in patients with head and neck cancer: A prospective longitudinal study. ( 30887617 )
2019
31
The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. ( 30888037 )
2019
32
The Effect of Watson's Care Model on Anxiety, Depression, and Stress in Turkish Women. ( 30888300 )
2019
33
Frequency of anxiety and depression in patients of urtolithiasis undergoing Extracorporeal Shock Wave Lithotripsy in Diyarbakir, Turkey. ( 30890841 )
2019
34
How does stress, depression and anxiety affect patients undergoing treatment? ( 30893136 )
2019
35
Case 9-2019: A 62-Year-Old Man with Atrial Fibrillation, Depression, and Worsening Anxiety. ( 30893540 )
2019
36
Comparing the effects of depression, anxiety and comorbidity on quality-of-life, adverse outcomes and medical expenditure in Chinese patients with acute coronary syndrome. ( 30896567 )
2019
37
Pathologic Use of Video Games and Motivation: Can the Gaming Motivation Scale (GAMS) Predict Depression and Trait Anxiety? ( 30897719 )
2019
38
Heat-killed Lactobacillus helveticus strain MCC1848 confers resilience to anxiety or depression-like symptoms caused by subchronic social defeat stress in mice. ( 30898081 )
2019
39
The relationship between smartphone addiction and symptoms of depression, anxiety, and attention-deficit/hyperactivity in South Korean adolescents. ( 30899316 )
2019
40
Association of vitamin B12 mediated hyperhomocysteinemia with depression and anxiety disorder: A cross-sectional study among Bhil indigenous population of India. ( 30904222 )
2019
41
Reversal effect of Riparin IV in depression and anxiety caused by corticosterone chronic administration in mice. ( 30904544 )
2019
42
Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4). ( 30904948 )
2019
43
Mindfulness and Symptoms of Depression and Anxiety in the General Population: The Mediating Roles of Worry, Rumination, Reappraisal and Suppression. ( 30906276 )
2019
44
Variations in grief, anxiety, depression, and health among family caregivers before and after the death of a close person in the context of palliative home care. ( 30907298 )
2019
45
What Lies Beyond the Superordinate Trait Perfectionism Factors? The Perfectionistic Self-Presentation and Perfectionism Cognitions Inventory Versus the Big Three Perfectionism Scale in Predicting Depression and Social Anxiety. ( 30907635 )
2019
46
The impact of resilience on prenatal anxiety and depression among pregnant women in Shanghai. ( 30831542 )
2019
47
Internalizing symptoms and chronotype in youth: A longitudinal assessment of anxiety, depression and tripartite model. ( 30832201 )
2019
48
Multiple Sclerosis, Anxiety, and Depression in the United Arab Emirates: Does Social Stigma Prevent Treatment? ( 30833870 )
2019
49
Exploring comorbidity between anxiety and depression among migrant Filipino domestic workers: A network approach. ( 30836284 )
2019
50
Does Peer Rejection Moderate the Associations among Cyberbullying Victimization, Depression, and Anxiety among Adolescents with Autism Spectrum Disorder? ( 30836698 )
2019